SEC Form 4 · accession 0001209191-15-078177
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stuart A Arbuckle
Officer — EVP\Chief Commercial Officer
Period of report
Oct 30, 2015
Accepted (ET)
Nov 3, 2015 · 6:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Oct 30, 2015 | S | 900 | $123.36 | D | 114,198 | D | |
| Common StockF2,F4 | Oct 30, 2015 | S | 1,000 | $124.44 | D | 113,198 | D | |
| Common StockF2,F5 | Oct 30, 2015 | S | 3,950 | $125.30 | D | 109,248 | D | |
| Common StockF2,F6 | Oct 30, 2015 | S | 4,500 | $126.31 | D | 104,748 | D | |
| Common Stock | holding | — | — | — | 140 | I | 401(k) |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
- F2Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F3Open market sales reported on this line occurred at a weighted average price of $123.36 (range $122.82 to $123.62).
- F4Open market sales reported on this line occurred at a weighted average price of $124.44 (range $123.85 to $124.80).
- F5Open market sales reported on this line occurred at a weighted average price of $125.30 (range $124.85 to $125.82).
- F6Open market sales reported on this line occurred at a weighted average price of $126.31 (range $125.86 to $126.78).